Vinita Bhagia, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1508060104
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,927 of the $4,804 with a category attached, or 60.9%. Sanofi-aventis U.S. LLC accounts for 67.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $4,281 and has fallen 97.7% since, to $100 in 2025.
Across 63 payments — averaging $76.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$3K
- Novo Nordisk$289
- AstraZeneca$191
- Valeritas, Inc.$182
- AbbVie$125
- Pulmonx Corporation$92
- plus $710 from 18 others
Across 7 payments — averaging $11,957 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$84K
What the payments were for
- Consulting fees$2,92761%
- Food & beverage$1,86439%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 11 | $3,216 |
| Novo Nordisk | 11 | $289 |
| AstraZeneca | 7 | $191 |
| Valeritas, Inc. | 5 | $182 |
| AbbVie | 1 | $125 |
| Pulmonx Corporation | 1 | $92 |
| Jazz Pharmaceuticals Inc. | 1 | $87 |
| Impulse Dynamics (USA) Inc. | 1 | $87 |
| Abbott | 3 | $56 |
| Biogen | 2 | $54 |
| Johnson & Johnson | 3 | $51 |
| Amgen | 1 | $50 |
| Radius Health, Inc. | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Philips North America LLC | 1 | $44 |
| Dexcom, Inc. | 2 | $34 |
| IBSA Pharma Inc. | 2 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$2,927
- TEFLARO$125
- Ozempic$125
- V-GO$122
How this compares
$4,804 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 340 | $402,943 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 131 | $277,940 |
| JardianceEmpagliflozin | 174 | $175,633 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 83 | $87,469 |
| MounjaroTirzepatide | 81 | $87,288 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $82,612 |
| TrulicityDulaglutide | 63 | $68,232 |
| FarxigaDapagliflozin Propanediol | 50 | $51,992 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $28,095 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $27,440 |
| JanuviaSitagliptin Phosphate | 22 | $26,930 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 23 | $21,972 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $18,738 |
| RybelsusSemaglutide | 13 | $12,161 |
| Novolog FlexpenInsulin Aspart | 38 | $9,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $289 | $693,044484 claims |
| Lilly USA, LLCMounjaro, Trulicity | $11 | $155,520144 claims |
| AstraZenecaFarxiga | $191 | $51,99250 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,216 | $27,44025 claims |
| AbbVieSynthroid | $125 | $2,52537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Andres SplenserHouston$923K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Laila TabatabaiHouston$207K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.